Free Trial
NYSE:ABT

Abbott Laboratories Q2 2025 Earnings Report

Abbott Laboratories logo
$134.77 +1.55 (+1.17%)
As of 11:22 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Abbott Laboratories EPS Results

Actual EPS
N/A
Consensus EPS
$1.25
Beat/Miss
N/A
One Year Ago EPS
N/A

Abbott Laboratories Revenue Results

Actual Revenue
N/A
Expected Revenue
$11.01 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Abbott Laboratories Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, July 17, 2025
Conference Call Time
9:00AM ET

Conference Call Resources

Abbott Laboratories Earnings Headlines

Andrew Abbott leads struggling Reds over Marlins
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Abbott Laboratories Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Abbott Laboratories? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Abbott Laboratories and other key companies, straight to your email.

About Abbott Laboratories

Abbott Laboratories (NYSE:ABT) (NYSE: ABT), founded in 1888 by Wallace C. Abbott, is a global healthcare company committed to discovering, developing and manufacturing a wide array of therapeutic and diagnostic products. Headquartered in Abbott Park, Illinois, the company has evolved from its pharmaceutical origins into a diversified provider of medical devices, diagnostics, nutrition and branded generic pharmaceuticals, serving patients and healthcare professionals in more than 160 countries.

The company’s medical devices division offers products designed to improve outcomes in cardiovascular care, neuromodulation and structural heart interventions. Its portfolio includes interventional cardiology tools, implantable cardiac rhythm management systems and neuromodulation therapies. In diagnostics, Abbott provides immunoassay and clinical chemistry platforms, point-of-care instruments, molecular diagnostics and rapid tests that enable accurate and timely clinical decisions across hospital laboratories, physician offices and remote settings.

In the nutrition segment, Abbott delivers science-based infant formulas, pediatric and adult nutritional products that support life-stage health and wellness. These offerings draw on the company’s expertise in vitamins, minerals and specialty nutrients to address global dietary needs. Abbott’s branded generics unit focuses on high-quality, cost-effective therapies in therapeutic areas such as women’s health, cardiovascular disease and metabolic disorders, with an emphasis on expanding access to medicines in emerging markets.

With a strong commitment to research and development, Abbott collaborates with academic institutions, healthcare providers and nonprofit organizations to drive medical innovation and improve patient care. Under the leadership of President and Chief Executive Officer Robert B. Ford, the company continues to uphold rigorous quality and regulatory standards while advancing its mission to enhance lives through pioneering healthcare solutions.

View Abbott Laboratories Profile

More Earnings Resources from MarketBeat